Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

Inclusion Criteria: 1. Patients aged between 18-65 years old; 2. Fulfilled the classification criteria of Takayasu's arteritis by ACR 1990; 3. relapse active TAK: defined by the definition of active disease in the recommendations released by EULAR in 2018; 4. Patients who signed the informed consent form. Exclusion Criteria: 1. Patients who failed or intolerant to either adalimumab or tofacitinib; 2. patients with severe liver disease defined by the serum ALT or AST elevated more than 2 times the upper limits; 3. not well controlled diabetes; 4. uncontrolled heart failure od renal dysfunction(eGFR\<30ml/min); 5. Patients with active infection,including tuberculosis, hepatitis B and C,HIV infection, bacteria or fungal infection; 6. upper GI bleeding 3 months before enrolement; 7. refractory hypertension; 8. Pregnant or intended to be pregnant 3 months after the trial; 9. Severe coronary artery involvement demonstrated by CTA; 10. severe cranial or cervical or renal artery diseases that need surgery; 11. Patients that should not be included by the investigator.